淋巴瘤中长春新碱诱导的神经病变发生率高。
High incidence of vincristine-induced neuropathy in lymphomas.
作者信息
Watkins S M, Griffin J P
出版信息
Br Med J. 1978 Mar 11;1(6113):610-2. doi: 10.1136/bmj.1.6113.610.
The incidence of vincristine-induced neuropathy was studied in 60 unselected patients, of whom 23 had lymphoma and 37 had other malignant disease. All were treated with vincristine combined with other cytotoxic agents. Fourteen of the patients with lymphoma (61%) developed neuropathy compared with five patients with leukaemia or non-lymphoid cancer (14%), even though all patients received comparable doses of vincristine. The difference between the two groups in the incidence of neuropathy was highly significant. Of the patients who developed neuropathy, 17 did so within the first three months of treatment and seven in the first month. Patients with lymphoma who are receiving vincristine should be observed carfully for symptoms and signs of neuropathy. Vincristine should be withdrawn if progressive neurotoxicity develops.
对60例未经挑选的患者进行了长春新碱诱发神经病变发生率的研究，其中23例患有淋巴瘤，37例患有其他恶性疾病。所有患者均接受长春新碱与其他细胞毒性药物联合治疗。14例淋巴瘤患者（61%）发生了神经病变，而白血病或非淋巴瘤癌症患者中有5例（14%）发生神经病变，尽管所有患者接受的长春新碱剂量相当。两组神经病变发生率的差异具有高度显著性。发生神经病变的患者中，17例在治疗的前三个月内出现，7例在第一个月内出现。接受长春新碱治疗的淋巴瘤患者应密切观察神经病变的症状和体征。如果出现进行性神经毒性，应停用长春新碱。
Zotero 插件